{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:22:08Z","timestamp":1778170928187,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jiac.2025.102627","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T12:30:08Z","timestamp":1737635408000},"page":"102627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Letermovir-inclusive combination therapy for a refractory and resistant infection by cytomegalovirus with UL54 mutation following a hematopoietic stem cell transplant for MHC class II deficiency"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2504-1696","authenticated-orcid":false,"given":"Noor Diana Ashaari","family":"Muhamad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Kanie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Otsubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyogo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazue","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5875-1024","authenticated-orcid":false,"given":"Yuho","family":"Horikoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102627_bib1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jcyt.2021.10.002","article-title":"Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients","volume":"24","author":"Camacho-Bydume","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jiac.2025.102627_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2478\/ahp-2020-0005","article-title":"Prophylaxis vs preemptive therapy in prevention of CMV infection: New insight on prophylactic strategy after allogeneic hematopoietic cell transplantation","volume":"51","author":"Styczy\u0144ski","year":"2020","journal-title":"Acta Haematol Pol"},{"key":"10.1016\/j.jiac.2025.102627_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for Use in clinical trials: 2024 Update from the transplant associated Virus infections Forum","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102627_bib4","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jtct.2021.09.010","article-title":"American Society for Transplantation and Cellular Therapy Series: #4 - cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation: ASTCT Guidelines on CMV treatment","volume":"27","author":"Yong","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jiac.2025.102627_bib5","series-title":"How I Treat How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","author":"Chaer","year":"2016"},{"key":"10.1016\/j.jiac.2025.102627_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-023-01617-1","article-title":"Letermovir for CMV prophylaxis in Very high-risk pediatric hematopoietic stem cell transplantation recipients for inborn errors of immunity","volume":"44","author":"C\u00e9sar","year":"2024","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jiac.2025.102627_bib7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41409-024-02209-2","article-title":"Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP)","volume":"59","author":"Galaverna","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jiac.2025.102627_bib8","volume":"vol. 83","author":"Saleem","year":"2000"},{"key":"10.1016\/j.jiac.2025.102627_bib9","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s10875-021-01112-5","article-title":"Hematopoietic cell transplantation for severe combined immunodeficiency patients: a Japanese retrospective study","volume":"41","author":"Miyamoto","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jiac.2025.102627_bib10","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1007\/s00431-022-04614-5","article-title":"Impact of cytomegalovirus infection prior to hematopoietic stem cell transplantation in children with inborn errors of immunity","volume":"181","author":"del Rosal","year":"2022","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jiac.2025.102627_bib11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation outcomes for severe combined immunodeficiency, 2000\u20132009","volume":"371","author":"Pai","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102627_bib12","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jaci.2021.04.015","article-title":"Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations","volume":"148","author":"Thalhammer","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jiac.2025.102627_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01231","article-title":"Spectrum of viral infections among primary immunodeficient children: report from a national registry","volume":"10","author":"Al-Herz","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jiac.2025.102627_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"JID (J Infect Dis)"},{"key":"10.1016\/j.jiac.2025.102627_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz480","article-title":"Analysis of ganciclovir-resistant cytomegalovirus infection caused by the UL97 gene mutation in Codons 460 and 520 in pediatric patients: a case Series","volume":"6","author":"Boonsathorn","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2025.102627_bib16","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkq368","article-title":"Drug-resistant cytomegalovirus in transplant recipients: a French cohort study","volume":"65","author":"Hantz","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102627_bib17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12185-021-03218-3","article-title":"Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation","volume":"115","author":"Jinnouchi","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jiac.2025.102627_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiac.2025.102627_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105623","article-title":"Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients","volume":"215","author":"Kleiboeker","year":"2023","journal-title":"Antivir Res"},{"key":"10.1016\/j.jiac.2025.102627_bib20","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40121-021-00452-4","article-title":"Cytomegalovirus infection and the Implications of drug-resistant mutations in pediatric allogeneic hematopoietic stem cell transplant recipients: a retrospective study from a Tertiary Hospital in China","volume":"10","author":"Yu","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2025.102627_bib21","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/infdis\/jiz578","article-title":"Letermovir resistance in hematopoietic stem cell transplant recipients: the risks associated with cytomegalovirus prophylaxis","volume":"221","author":"James","year":"2020","journal-title":"JID (J Infect Dis)"},{"key":"10.1016\/j.jiac.2025.102627_bib22","first-page":"149","article-title":"Leflunomide: a treatment option for ganciclovir-resistant cytomegalovirus infection after renal transplantation","volume":"2","author":"Andrassy","year":"2009","journal-title":"NDT Plus"},{"key":"10.1016\/j.jiac.2025.102627_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.948210","article-title":"Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: a case report","volume":"9","author":"Su","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.jiac.2025.102627_bib24","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-128766","article-title":"Efficacy of artesunate for treatment of cytomegalovirus reactivations in allogeneic Haematopoietic stem cell transplant recipients who are Intolerant\/Unsuitable for ganciclovir therapy","volume":"134","author":"Shenoy","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jiac.2025.102627_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010370","article-title":"Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers","volume":"5","author":"Arav-Boger","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2025.102627_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.11785","article-title":"New treatment options for refractory\/resistant CMV infection","volume":"36","author":"Walti","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.jiac.2025.102627_bib28","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/jpids\/piad059","article-title":"Current and emerging antiviral agents in the prevention and treatment of cytomegalovirus in pediatric transplant recipients","volume":"13","author":"Deray","year":"2024","journal-title":"J Pediatric Infect Dis Soc"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25000236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25000236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:49:34Z","timestamp":1762368574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25000236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1341321X25000236"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102627","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letermovir-inclusive combination therapy for a refractory and resistant infection by cytomegalovirus with UL54 mutation following a hematopoietic stem cell transplant for MHC class II deficiency","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102627"}}